Pill-on-a-Thread: New Hope for Esophageal Cancer Screening
- A less invasive capsule sponge test could replace endoscopies for half the patients monitored for esophageal cancer risk, according to a study published in The Lancet.
- The capsule sponge, also known as a "pill-on-a-thread," is easier to administer and could be performed by nurses at GP practices.
- Fewer than 20% of patients survive five years post-diagnosis, a figure that has remained relatively unchanged for three decades.
discover a groundbreaking advancement in esophageal cancer screening! A new “pill-on-a-thread” is poised to revolutionize monitoring, potentially replacing invasive endoscopies for many patients. This less invasive capsule sponge test, easier to administer and potentially performed by nurses, is promising a important shift in how we detect the primary_keyword. The study,published in The Lancet,highlights how the secondary_keyword impacts the early detection of the challenging-to-treat disease while also aiming to reduce the strain on healthcare resources. Esophageal cancer diagnoses have surged, underscoring the urgent need for improved screening methods. This innovative approach could offer a more patient-friendly pathway to early detection and treatment, ultimately boosting survival rates. News Directory 3 reported this vital growth. Explore the crucial role of early detection, the potential impact on treatment, and the future of esophageal cancer care. Discover what’s next …
‘Pill-on-a-thread’ Could Replace Endoscopies for Esophageal Cancer Monitoring
A less invasive capsule sponge test could replace endoscopies for half the patients monitored for esophageal cancer risk, according to a study published in The Lancet. Researchers from the University of Cambridge, Addenbrooke’s Hospital, and Queen Mary university of London conducted the study.
The capsule sponge, also known as a “pill-on-a-thread,” is easier to administer and could be performed by nurses at GP practices. This could significantly reduce the burden on resources, researchers said.
Esophageal cancer is a challenging-to-treat disease. Fewer than 20% of patients survive five years post-diagnosis, a figure that has remained relatively unchanged for three decades. Meanwhile,diagnoses have increased four-fold since the 1970s.
Barrett’s Esophagus and the Pill Test
Barrett’s esophagus, a condition where cells in the esophagus change, is a known risk factor for esophageal cancer. These cells initially resemble those in the intestines but can progress to a precancerous state called dysplasia.
Dysplasia is categorized as low-grade or high-grade. Patients with low-grade dysplasia have a 10% risk of developing esophageal cancer, while those with high-grade dysplasia face a 20% risk. Treatment can address dysplasia, significantly lowering future cancer risk.
Barrett’s esophagus is typically diagnosed via endoscopy after a patient reports persistent heartburn. However, the National health Service (NHS) faces long waiting times for these initial investigations.
Once diagnosed, patients undergo regular endoscopies to monitor for dysplasia or early cancer. Early detection improves treatment success,potentially allowing for day-case endoscopic treatment without chemotherapy or surgery.
Rebecca Fitzgerald, director of the Early Cancer Institute at the University of Cambridge and honorary consultant gastroenterologist at Addenbrooke’s Hospital, specializes in Barrett’s esophagus. she said monitoring is crucial to catch and treat dysplasia before it develops into cancer.
Fitzgerald added that endoscopies are unpleasant, and their reliability in spotting early cancers can vary. She said an option, less invasive, easier-to-administer, and more reliable surveillance method is needed.
What’s next
Researchers plan to conduct further studies to refine the capsule sponge test and expand its use in primary care settings, potentially transforming esophageal cancer monitoring and improving patient outcomes.